Group 1 - The core viewpoint of the article is that Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - Lingke Pharmaceutical is a leading pharmaceutical company based in China, focusing on the development of innovative drugs for the treatment of tumors, immune diseases, and inflammatory conditions [1] - The company was founded by experienced drug development experts, and its team has extensive experience in drug discovery [1] Group 2 - The company has made significant progress in its product development pipeline, with core products LNK01001 and LNK01004 advancing, and the first candidate product expected to enter the preclinical stage [1] - The commercialization of the core product LNK01001 has been fully entrusted to Sihuan Pharmaceutical, with an agreement to share sales revenue, although specific details on the revenue split, sales targets, and minimum purchase quantities have not been disclosed in the prospectus [1]
凌科药业递交赴港IPO申请，核心产品LNK01001的商业化已全权委托先声药业